Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus 2.0

Abstract

Gestational diabetes mellitus (GDM) has become a major public health problem and one of the most discussed issues in modern obstetrics. GDM is associated with serious adverse perinatal outcomes and long‐term health consequences for both the mother and child. Currently, the importance and purposefulness of finding a biopredictor that will enable the identification of women with an increased risk of developing GDM as early as the beginning of pregnancy are highly emphasized. Both “older” molecules, such as adiponectin and leptin, and “newer” adipokines, including fatty acid‐binding protein 4 (FABP4), have proven to be of pathophysiological importance in GDM. Therefore, in our previous review, we presented 13 novel biomolecules, i.e., galectins, growth differentiation factor‐15, chemerin, omentin‐1, osteocalcin, resistin, visfatin, vaspin, irisin, apelin, FABP4, fibroblast growth factor 21, and lipocalin‐2. The purpose of this review is to present the potential and importance of another nine lesser known molecules in the pathogenesis of GDM, i.e., 3‐carboxy‐4‐methyl‐5‐propyl‐2‐furanpropanoic acid (CMPF), angiopoietin‐like protein‐8 (ANGPTL‐8), nesfatin‐1, afamin, adropin, fetuin‐A, zonulin, secreted frizzled‐related proteins (SFRPs), and amylin. It seems that two of them, fetuin‐A and zonulin in high serum levels, may be applied as biopredictors of GDM.